Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/184795
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invite to open peer review
Title

Antibodies to paraoxonase 1 are associated with oxidant status and endothelial activation in rheumatoid arthritis

AuthorsRodríguez-Carrio, Javier CSIC ORCID; Alperi-López, Mercedes; López-Mejías, Raquel; López, Patricia CSIC ORCID; Ballina García, Francisco Javier; Abal, Francisco; González-Gay, M. A.; Suárez, Ana
KeywordsAnti-paraoxonase 1 antibodies
Cardiovascular disease
High-density lipoproteins
Paraoxonase
Rheumatoid arthritis
Issue Date22-Sep-2016
PublisherPortland Press
CitationClinical Science 130 (21): 1889-1899 (2016)
AbstractTraditional and non-traditional cardiovascular (CV) risk factors underlie CV disease occurrence in rheumatoid arthritis (RA). Recently, a functional impairment of high-density lipoprotein (HDL) has been observed. Although the actual players are unknown, anti-HDLs were associated with altered lipid profile, decreased paraoxonase 1 (PON1) activity and CV disease in RA. Therefore, we aimed to evaluate whether the presence of antibodies against PON1 may be involved in this scenario. IgG anti-PON1 antibodies were quantified by ELISA in serum samples from 212 RA patients, 175 healthy controls (HC) and 54 subjects with traditional CV risk factors (CVR). A subgroup of 13 RA patients was prospectively followed upon tumour necrosis factor-α (TNFα) blockade. Serum PON1 activity, nitric oxide (NO) and total antioxidant capacity (TAC) were measured. Interferon-γ (IFNγ), interleukin 8 (IL-8), monocyte chemotactic protein 1 (MCP-1), vascular endothelial growth factor (VEGF), soluble intercellular adhesion molecule (sICAM) and TNFα serum levels were assessed by immunoassays. PON1 rs662 (Q > R) status was studied by reverse transcription (RT)–PCR. IgG anti-PON1 antibodies are increased in RA patients compared with HC (P<0.0001) and CVR subjects (P<0.001), even after correcting for total IgG levels. Although no associations with lipid profile were found, a positive correlation with Health Assessment Questionnaire (HAQ) was observed (r=0.215, P=0.004). Anti-PON1 antibodies were associated with PON1 activity, NO and TAC, a rs662-mediated gene-dosage effect being found. Similarly, anti-PON1 antibodies were associated with sICAM serum levels in univariate and multivariate models. Finally, these antibodies were not affected by TNFα blockade. Anti-PON1 antibodies can be responsible for PON1 impairment in RA patients, with a potential impact on biomarkers of oxidative status and endothelial activation. A gene–environment interaction of rs662 variants is supported.
Publisher version (URL)http://dx.doi.org/10.1042/CS20160374
URIhttp://hdl.handle.net/10261/184795
DOI10.1042/CS20160374
ISSN0143-5221
E-ISSN1470-8736
Appears in Collections:(IPLA) Artículos




Files in This Item:
File Description SizeFormat
accesoRestringido.pdf15,35 kBAdobe PDFThumbnail
View/Open
Show full item record

CORE Recommender

SCOPUSTM   
Citations

14
checked on May 14, 2024

WEB OF SCIENCETM
Citations

14
checked on Feb 25, 2024

Page view(s)

280
checked on May 20, 2024

Download(s)

34
checked on May 20, 2024

Google ScholarTM

Check

Altmetric

Altmetric


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.